| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,800 | 1,820 | 18.07. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.06. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 04.06. | Dividendenbekanntmachungen (04.06.2026) | 14.276 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-LIVING SMART CITY SERVICES CO LTD CNE100002RY5 0,0688 HKD 0,0075 EUR ADESSO SE DE000A0Z23Q5 - 0,78 EUR AGEAS SA/NV ADR US00844W2089 2... ► Artikel lesen | |
| 29.05. | HAOHAI BIOTEC (06826): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 (UPDATED) | - | HKEx | ||
| SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 29.05. | HAOHAI BIOTEC (06826): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 29.05. | HAOHAI BIOTEC (06826): RESIGNATION OF AN EXECUTIVE DIRECTOR; CHANGE OF THE CHAIRMAN; AND CHANGE OF COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| 29.05. | HAOHAI BIOTEC (06826): POLL RESULTS OF AGM, A SHAREHOLDERS' CLASS MEETING AND H SHAREHOLDERS' CLASS MEETING; 2025 PROFIT DISTRIBUTION; CHANGE OF DIRECTORS ... | - | HKEx | ||
| 15.05. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 06.05. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 30.04. | HAOHAI BIOTEC (06826): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD. ANNOUNCEMENT ON THE RECEIPT OF THE "DECISION ... | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 (UPDATED) | 2 | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): FORM OF PROXY FOR THE 2026 FIRST H SHAREHOLDERS' CLASS MEETING TO BE HELD ON FRIDAY, 29 MAY 2026 | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): FORM OF PROXY FOR THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 29 MAY 2026 | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): NOTICE OF 2026 FIRST H SHAREHOLDERS' CLASS MEETING | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): NOTICE OF 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING AND 2026 FIRST H SHAREHOLDERS' CLASS MEETING | - | HKEx | ||
| 27.04. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | - | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF DEPUTY GENERAL MANAGERS | 1 | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): 2026 FIRST QUARTERLY REPORT | 1 | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | 2 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,146 | -0,51 % | WARNUNG für Valneva-Anleger: Was sich hinter den Kulissen tut - Was ich dieses Wochenende analysiert habe | ||
| AMGEN | 318,50 | -0,52 % | After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset | ||
| STRYKER | 280,10 | +0,21 % | Stryker fully launches Mako robotic power system for knee surgery in US | ||
| REGENERON PHARMACEUTICALS | 590,00 | -0,25 % | Bayer, Regeneron und Emyria: Warum der nächste Pharmatrend nicht aus dem Milliardenmarkt, sondern aus einer neuen Therapiegeneration kommen könnte | ||
| CSL | 75,86 | +0,73 % | Here's why I'd buy and hold CSL and Cochlear shares for 10 years | ||
| BEONE MEDICINES LTD ADR | 272,00 | -1,45 % | BEONE MEDICINES (06160): DATE OF SECOND QUARTER 2026 FINANCIAL RESULTS ANNOUNCEMENT AND NOTICE OF AUDIT COMMITTEE ACTION | ||
| CANSINO BIOLOGICS | 2,700 | +4,65 % | CanSino Biologics Inc: CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Further Expanding International Presence in South America | HONG KONG, June 29, 2026 - (ACN Newswire) - On June 25, CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) announced that the Company's ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)... ► Artikel lesen | |
| BIOMERIEUX | 73,05 | +1,32 % | Dividendenbekanntmachungen (09.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMEREN CORPORATION US0236081024 0,75 USD 0,6501 EUR AMUNDI SA FR0004125920 - 4,25 EUR BECTON DICKINSON AND COMPANY US0758871091 1... ► Artikel lesen | |
| SINO BIOPHARM | 0,547 | -1,87 % | SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - TRD205 "AT2R ANTAGONIST" GRANTED THE CDE'S BREAKTHROUGH THERAPY DESIGNATION | ||
| ZAI LAB LTD ADR | 17,100 | -3,39 % | Zai Lab Limited: Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas | Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,518 | +2,70 % | EQS Newswire: CStone Pharmaceuticals: CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights | EQS Newswire / 12/06/2026 / 15:02 UTC+8
Shanghai - 12 Jun 2026 - The clinical datasets presented at ASCO 2026 further validate the trispecific synergistic mechanism of CS2009 and support its potential... ► Artikel lesen | |
| CASI PHARMACEUTICALS | 0,214 | -4,13 % | CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer | ||
| 3SBIO | 1,747 | -9,68 % | 3SBio Inc.: 3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone | SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK) today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs... ► Artikel lesen | |
| QIAGEN | 35,965 | -0,55 % | Siemens Energy fällt zurück, Qiagen zieht an: DAX-Ausblick | Der DAX ist nach seinem Rekordlauf in der vergangenen Woche wieder etwas zurückgekommen. Unter dem Strich büßte das größte deutsche Börsenbarometer unter dem Strich mehr als 700 Punkte ein und schloss... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,99 | -0,01 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen |